Lataa...
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
BACKGROUND: Long-acting injectable cabotegravir (CAB LA) is a novel integrase inhibitor in advanced clinical development for HIV treatment and HIV prevention. We investigated the terminal pharmacokinetics and safety of CAB LA after final injection as part of a Phase 2 study. METHODS: We performed a...
Tallennettuna:
| Julkaisussa: | Lancet HIV |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7859863/ https://ncbi.nlm.nih.gov/pubmed/32497491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(20)30106-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|